NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🔴 Neurosense Therapeutics is trading 18.3% down in after-hours trading — no specific cause established
Neurosense Therapeutics is trading at $2.85, down 18.34% in after-hours trading; available evidence does not establish a specific cause. - Nasdaq appeal...
NeuroSense Buys Time on Nasdaq, but Can a $13 Million Biotech Close a $35 Million Gap Before the Clock Runs Out?
Shares of NeuroSense Therapeutics surged 13.2% to $3.95 after the company disclosed that a Nasdaq Hearings Panel will review its delisting appeal on November...
🟢 Neurosense Therapeutics is trading 13.2% up in after-hours trading amid Nasdaq appeal update
Neurosense Therapeutics is trading 13.2% up at $3.95 after closing at $3.49 on October 13; the Nasdaq update is a plausible company-specific catalyst, but the...
🟢 Neurosense Therapeutics is trading 6.9% up in after-hours trading — catalyst remains unconfirmed
Neurosense Therapeutics is trading 6.9% higher at $3.73 after hours; the catalyst remains unconfirmed. - It closed at $3.49 on October 13, after...
🟢 Neurosense Therapeutics is trading 10% up today with Nasdaq hearing scheduled for November 10
Neurosense Therapeutics is trading at $3.78, up +9.68%; coverage does not directly tie the gain to a catalyst. - The company announced October 13 that its...
🔴 Neurosense Therapeutics is trading 10.38% down today; catalyst remains unclear
Neurosense Therapeutics is trading 10.38% down at $3.28, with no confirmed company-specific catalyst identified for October 12. - The company’s news list...
🔴 Neurosense Therapeutics is trading 5% down with no confirmed catalyst
Neurosense Therapeutics is trading 5.46% lower at $3.46, with no confirmed catalyst identified in the sources reviewed. - No company-specific announcement...
🟢 Neurosense Therapeutics rises 6.3% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Neurosense Therapeutics is trading 5.5% down today as XBI falls more than 2%
Neurosense Therapeutics is trading 5.5% down at $3.61, with biotech and broader-market weakness the strongest available explanation. - The XBI is down more...
🔴 Neurosense Therapeutics is trading 6% down on October 7, 2026, amid biotech-sector weakness
Neurosense Therapeutics is trading at $3.82, down 6.14%, with biotech-sector weakness the clearest context; no direct company-specific catalyst was...
🟢 Neurosense Therapeutics is trading 6.2% up — Nasdaq appeal not confirmed as catalyst
Neurosense Therapeutics is trading 6.2% up at $4.28, with available sources not establishing a direct cause for the October 6 intraday rise. - On October 2,...
NeuroSense Fights to Stay on Nasdaq — But Can a Small Biotech Buy Enough Time to Survive?
Shares of NeuroSense Therapeutics surged 15.4% to $4.54 on October 5, snapping a five-session slide, after the company disclosed plans to appeal Nasdaq's move...
🟢 Neurosense Therapeutics is trading 15.4% up today amid plan to appeal Nasdaq compliance determination
Neurosense Therapeutics is trading 15.4% higher at $4.54; its October 2 plan to appeal Nasdaq’s minimum market-value determination is the clearest relevant...
🟢 Neurosense Therapeutics is trading 6.23% up today amid planned appeal of Nasdaq delisting determination
Neurosense Therapeutics is trading at $4.18, up 6.23% on October 5; no catalyst was identified. - On October 2, the company said it had failed Nasdaq’s $35...
🔴 Neurosense Therapeutics is trading 5.2% down in after-hours trading after reported Nasdaq delisting determination
Neurosense Therapeutics is trading 5.2% lower at $3.73 after-hours on October 2 after a reported Nasdaq delisting determination for missing the $35 million...
NeuroSense Plans Nasdaq Appeal After Missing $35 Million Market-Value Rule
NeuroSense Therapeutics said on October 2, 2026, that it received a Nasdaq delisting determination notice dated October 1. The notice says the company failed...
🔴 Neurosense Therapeutics is trading 5.7% down after six previous-session declines
Neurosense Therapeutics is trading at $3.82, down 5.68%, with no clear company-specific catalyst identified for the October 2, 2026 decline. - The...
🔴 Neurosense Therapeutics is trading 6.1% down
Neurosense Therapeutics is trading 6.09% down at $4.16 on October 1, 2026; no clear company-specific catalyst for the decline was identified. - The decline...
🔴 Neurosense Therapeutics is trading 5.4% down in pre-market
Neurosense Therapeutics is trading 5.42% lower at $4.19 in pre-market on October 1, 2026; no clear company-specific catalyst has been identified. - Shares...
🔴 Neurosense Therapeutics is trading 5% down in after-hours trading
Neurosense Therapeutics is trading 5.19% lower at $4.20 after-hours, with no clear company-specific catalyst identified. - Shares closed September 30, 2026, at...